ATMP Sweden ATMP Sweden Current initiatives CAMP CAMP Projects Extracellular vesicles

Extracellular vesicles

Extracellular vesicles (CARMEV) for prevention of heart failure (continuation)

The overall goal is to develop extracellular vesicles (EVs) from bone marrow MSCs
to inhibit I/R injury after myocardial infarction (MI) -> heart failure prevention

Time period: 11/2021 – 11/2023

Lead: Karl-Henrik Grinnemo, Uppsala University Hospital

Involved partners: Uppsala University Hospital, Uppsala University, AstraZeneca.

EVs from BM-MSCs (patented technology) inhibit apoptosis of cardiomyocytes, stimulate angiogenesis and preserve the myocardial function including the extracellular matrix structure after ischemia-reperfusion injury in mice.

Work plan:

  • dose-response assays, characterize the biologically active EV preparations
  • confirm the safety of the EV product in animal experiments and human in vitro tests (biodistribution assays, complement activation assays, coagulation assay)
  • generation of a final well-characterized EV product under GMP conditions.
  • initiate contact with the Swedish MPA (Läkemedelsverket).